Program
selatogrel
Also written as “Selatogrel”, “ACT-246475” and “Selatogrel 8 mg”.
Its studies are mostly in Myocardial Infarction · Coronary Artery Disease, led by 2 companies.
Drug pageSelatogrel: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 101 open or running | phase 3since Jun 28, 2021 | Dec 20, 2017 | Jul 2027phase 3 · NCT04957719 |
| Idorsia Pharmaceuticals | 10 open or running | phase 1since Sep 27, 2013 | Sep 27, 2013 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Idorsia Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 27, 2013First study: phase 1 study in Safety, Tolerability, Pharmacokinetics and PharmacodynamicsFirst studyNCT01954615 · 49 enrolled · France
- Jun 9, 2018Named selatogrelINNProposed as its International Nonproprietary Name in WHO's List 119 · before, ACT-246475
TargetBeta
“Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule
Other programs on P2RY12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Clopidogrelrule | Sanofi | phase 4 | 71 |
| Ticagrelorrule | AstraZeneca | phase 4 | 47 |
Studies
The one study Idorsia Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01954615Safety, Tolerability, Pharmacokinetics and Pharmacodynamics · France | 1 | Completed | Mar 2012 | 49 |
How it is read
Names in the registry
- “Selatogrel”, 8 entries
- “ACT-246475”, 3 entries
- “Selatogrel 8 mg”, 1 entry
- “Selatogrel 16 mg”, 1 entry
- “ACT-246475 (Group G dose to be defined)”, 1 entry
Conditions, from the studies’ own filings
- Myocardial Infarction, 2 studies
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.